Zoonoses

Todos Medical CEO Releases Letter to Shareholders

Friday, September 18, 2020 - 3:04pm

NEW YORK, REHOVOT, Israel and SINGAPORE, Sept. 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), anin vitrodiagnostics company focused on developing and distributing comprehensive solutions for COVID-19, and developing blood tests for the early detection of cancer and Alzheimers disease, today released a letter to shareholders from CEO Gerald Commissiong:

Key Points: 
  • NEW YORK, REHOVOT, Israel and SINGAPORE, Sept. 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), anin vitrodiagnostics company focused on developing and distributing comprehensive solutions for COVID-19, and developing blood tests for the early detection of cancer and Alzheimers disease, today released a letter to shareholders from CEO Gerald Commissiong:
    2020 has been quite the year for Todos Medical.
  • Todos Medical has established a comprehensive suite of testing solutions for addressing the COVID-19 crisis.
  • We see this as a huge growth opportunity for Todos that could generate sufficient cash flow to also support our cancer and Alzheimers testing business.
  • In conclusion, 2020 has shown the resilience of Todos Medical.

EPA Approves SteriCide™ Disinfectant for Use Against SARS-CoV-2 (COVID-19)

Friday, September 18, 2020 - 3:00pm

SteriCide has demonstrated effectiveness against viruses similar to Severe Acute Respiratory Syndrome Coronavirus [2 SARS-CoV-2] on hard, non-porous surfaces.

Key Points: 
  • SteriCide has demonstrated effectiveness against viruses similar to Severe Acute Respiratory Syndrome Coronavirus [2 SARS-CoV-2] on hard, non-porous surfaces.
  • Therefore, SteriCide can be used against Severe Acute Respiratory Syndrome Coronavirus [2 SARS-CoV-2] when used in accordance with the directions for sterilization on hard, non-porous surfaces.
  • Make sure to follow the contact time, which is the amount of time a surface should be visibly wet, for full efficacy.
  • SteriCide stands out as not only a disinfectant, but an all-in-one disinfectant, sterilant, detergent cleaner, deodorizer, fungicide, and sporicide.

Generex Signs Binding Licensing & Research Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia

Friday, September 18, 2020 - 2:00pm

Under terms of the deal, Generex and Bintai have agreed to collaborate and have developed a strategy towards the rapid development of the Ii-Key-CoV-2 vaccine for Malaysia.

Key Points: 
  • Under terms of the deal, Generex and Bintai have agreed to collaborate and have developed a strategy towards the rapid development of the Ii-Key-CoV-2 vaccine for Malaysia.
  • Generex CEO, Joseph Moscato said, We want to thank our partners at Bintai for their commitment to develop our Ii-Key-SARS-CoV-2 Complete Vaccine against COVID-19.
  • Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
  • Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Logistics Market - Roadmap for Recovery from COVID-19 | Increasing Cross-Border Trade to Boost the Market Growth | Technavio

Friday, September 18, 2020 - 1:00pm

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities.
  • Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis.
  • Download a Free Sample Report on COVID-19 Impacts
    Based on segmentation by end-user, which is the leading segment in the market?

Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance

Friday, September 18, 2020 - 9:00am

The study demonstrated a 10-fold reduction in COVID-19 viral population on surfaces using 3F Biofragrance.

Key Points: 
  • The study demonstrated a 10-fold reduction in COVID-19 viral population on surfaces using 3F Biofragrance.
  • We designed 3F Biofragrance to solve this issue through a multi-focal approach to inhibiting viruses that reduces the chances of developing resistance as seen with other antimicrobials."
  • In the latest study, 3F Biofragrance demonstrated success as a surface disinfectant, killing the COVID-19 virus in concentrations as low as 1/5000 or 0.02%.
  • Impact BioLife is currently in joint development with multiple global cosmetics and consumer products companies for the commercialization of the 3F Biofragrance technology.

NRL, NCATS Scientists Develop Method to Safely Study COVID-19, Other Contagious Diseases

Thursday, September 17, 2020 - 8:11pm

"We developed nanoparticle-based pseudo-virions that bind to the host cell and track themselves inside of cells without being contagious," said Eunkeu Oh, Ph.D., an NRL biophysicist.

Key Points: 
  • "We developed nanoparticle-based pseudo-virions that bind to the host cell and track themselves inside of cells without being contagious," said Eunkeu Oh, Ph.D., an NRL biophysicist.
  • "This opens an opportunity to expand the same strategy to various other infectious diseases."
  • Together with researchers at NCATS, part of the National Institutes of Health (NIH), they worked to develop non-infectious probes to study SARS-CoV-2, which is the causative virus of the current COVID-19 pandemic.
  • "Merging our resources with the NCATS team's expertise resulted in research that couldn't be done by one team on its own."

COVID-19 Recovery Analysis: Biologic Therapeutics Market | Strong R&D Pipeline to Boost the Market Growth | Technavio

Thursday, September 17, 2020 - 7:00pm

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • View the full release here: https://www.businesswire.com/news/home/20200917005704/en/
    Technavio has announced its latest market research report titled Global Biologic Therapeutics Market 2020-2024 (Graphic: Business Wire)
    Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied.
  • Strong R&D pipeline has been instrumental in driving the growth of the market.
  • Download a Free Sample Report on COVID-19 Impacts
    Biologic Therapeutics Market is segmented as below:

DeciBio Consulting Launches Emmes SARS-CoV-2 Testing Database

Thursday, September 17, 2020 - 6:45pm

DeciBio Consulting, a strategy consulting firm dedicated to the precision medicine space, has launched the Emmes SARS-CoV-2 Testing Database.

Key Points: 
  • DeciBio Consulting, a strategy consulting firm dedicated to the precision medicine space, has launched the Emmes SARS-CoV-2 Testing Database.
  • Such products include the Emmes Infectious Disease Database, the Emmes Oncology Database, BioMAP (immuno-oncology biomarkers), Marketbooks, Dexter, and BioTrack, among others.
  • The DeciBio Emmes SARS-CoV-2 Testing Database provides data visualization tools and raw data covering coronavirus testing practices in approximately 400 labs in the United States.
  • To learn more about the SARS-CoV-2 Testing Database or to schedule a demo, visit https://www.decibio.com/intelligence/emmes-databases/
    DeciBio Consulting is a strategy consulting firm focused on precision medicine.

ams Introduces Ultra-thin Sensor Bringing New Blood-Oxygen Monitoring Capability to Earbuds, Patches, and Other Wearable Devices

Thursday, September 17, 2020 - 4:00pm

The development of a wearable SpO2 measurement device based on the AS7038RB can be used remotely and therefore help in the treatment of people infected with the SARS-CoV-2 virus.

Key Points: 
  • The development of a wearable SpO2 measurement device based on the AS7038RB can be used remotely and therefore help in the treatment of people infected with the SARS-CoV-2 virus.
  • Wim Renirie, Vice President and General Manager for the Accessory and Wearable Solutions Business Line at ams, said: The introduction of the AS7038RB marks another ams breakthrough in technology for remote diagnostics.
  • ams is working actively with a range of partners to develop innovative solutions for the testing and diagnosis of COVID-19.
  • A modular version, the AS7030B HRM/HRV sensor, integrates two 535nm LEDs in a single package measuring 3.55mm x 6.2mm x 1mm.

Diomics Announces Agreement With Department of Defense to Accelerate Development and Testing of Diocheck™ SARS-CoV-2 Immune Response Indicator Patch

Thursday, September 17, 2020 - 3:00pm

The patch begins to detect an immune response within 24 to 36 hours of application and is expected to effectively monitor for up to 14 days.

Key Points: 
  • The patch begins to detect an immune response within 24 to 36 hours of application and is expected to effectively monitor for up to 14 days.
  • The Diocheck patch answers one of the biggest roadblocks to halting the spread of COVID-19a simple, universal way for people to continually monitor their own immune status over an extended period of time.
  • The Diocheck patch responds to the great unknown of how many people are unintentionally widening the spread by being asymptomatic carriers, Diomics CEO Anthony Zolezzi said.
  • Widespread use of the Diocheck indicator patch will give us a simple, effective, non-invasive way to know that we are all actively protecting each other.